MCM
TVTX icon

MAI Capital Management’s Travere Therapeutics TVTX Stock Holding History

MAI Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7K Buy
563
+232
+70% +$6.93K ﹤0.01% 2894
2025
Q4 		$12.6K Buy
+331
New +$10.8K ﹤0.01% 2744

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAI Capital Management's TVTX Position: Q1 2026 in Review

MAI Capital Management increased its Travere Therapeutics (TVTX) stake by 70% in Q1 2026, buying an estimated $6.93K and bringing the position to 563 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2894.

MAI Capital Management first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • MAI Capital Management held 563 shares of Travere Therapeutics worth $16.7K as of Q1 2026.
  • MAI Capital Management bought 232 Travere Therapeutics shares in Q1 2026, an estimated $6.93K.
  • Travere Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2894 holding.
  • MAI Capital Management first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.